Download References: These guidelines are prepared from multiple practice

References:
These guidelines are prepared from multiple practice guidelines available.
http://www.esmo.org
http://www.bccancer.bc.ca
http://www.nccn.org
http://www.asco.org
Uptodate.com
1. Tamoxifen for prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project P-1 Study. Fisher B, Costantino JP,
Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A,
Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. J Natl
Cancer Inst. 1998;90(18):1371.
2. Twenty-year follow-up of the Royal Marsden randomized, double-blinded
tamoxifen breast cancer prevention trial. Powles TJ, Ashley S, Tidy A, Smith
IE, Dowsett M. J Natl Cancer Inst. 2007;99(4):283.
3. Italian randomized trial among women with hysterectomy: tamoxifen and
hormone-dependent breast cancer in high-risk women. Veronesi U,
Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G,
Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A,
Robertson C, Boyle P, Italian Tamoxifen Study Group. J Natl Cancer Inst.
2003;95(2):160.
4. Long-term results of tamoxifen prophylaxis for breast cancer--96-month
follow-up of the randomized IBIS-I trial. Cuzick J, Forbes JF, Sestak I,
Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer
Intervention Study I Investigators. J Natl Cancer Inst. 2007;99(4):272.
5. Overview of the main outcomes in breast-cancer prevention trials. Cuzick J,
Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Lancet.
2003;361(9354):296.
6. Update of the National Surgical Adjuvant Breast and Bowel Project Study of
Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN,
Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese
RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG,
Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project
Cancer Prev Res (Phila). 2010;3(6):696
7. Exemestane for breast-cancer prevention in postmenopausal women. Goss
PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende
J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE,
Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D,
Richardson H, NCIC CTG MAP.3 Study, N Engl J Med. 2011;364(25):2381.
8. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the
breast: recommendations from the EUSOMA working group. Eur J Cancer
2010;46:1296-1316.
9. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for
human epidermal growth factor receptor 2 testing in breast cancer. J Clin
Oncol 2007;25:118-145.
10. www.cap.org
11. Association of Breast Surgery at Baso 2009. Surgical guidelines for the
management of breast cancer. Eur J Surg Oncol 2009;35 Suppl 1:1-22.
12. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy
and of differences in the extent of surgery for early breast cancer on local
recurrence and 15-year survival: an overview of the randomised trials.
Lancet 2005;366:2087-2106.
13. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection
compared with conventional axillary-lymph-node dissection in clinically
node-negative patients with breast cancer: overall survival findings from the
NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-933.
14. Morrow M. Breast conservation and negative margins: how much is enough?
Breast 2009;18 Suppl(3):S84-S86.
15. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors in
breast cancer. J Clin Oncol 2010;28:2784-2795.
16. Goldhirsch A, Ingle JN, Gelber RD, et al Thresholds for therapies: highlights
of the St Gallen International Expert Consensus on the primary therapy of
early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
17. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant
chemotherapy for premenopausal women with lymph node-positive breast
cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol
2006;24:1332-1341.
18. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for
premenopausal women with axillary lymph node-positive, steroid hormone
receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol
2005;23:5973-5982.
19. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormonereleasing hormone agonists as adjuvant treatment in premenopausal patients
with hormone-receptor-positive breast cancer: a meta-analysis of individual
patient data from randomised adjuvant trials. Lancet 2007;369:1711-1723.
20. ATAC Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and
tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month
analysis of the ATAC trial. Lancet Oncol 2008;9:45-53. Colleoni M,
21. Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover
show improved overall survival with adjuvant letrozole compared with
tamoxifen in the BIG 1–98 study. J Clin Oncol 2011;29:1117-1124.
22. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of
exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment
(Intergroup Exemestane Study): a randomised controlled trial. Lancet
2007;369:559-570. Dowsett M,
23. Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant
trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518.
24. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant
therapy according to estrogen receptor and progesterone receptor status of
the primary tumor: National Cancer Institute of Canada Clinical Trials
Group MA.17. J Clin Oncol 2007;25:2006-2011. 57.↵
25. Leyland-Jones B, Regan M, Bouzyk M, et al. Outcome according to CYP2D6
genotype among postmenopausal women with endocrine-responsive early
invasive breast cancer randomized in the BIG 1-98 trial. Cancer Res 2010;70.
S1–S8. Rae J,
26. Drury S, Hayes D, et al. Lack of correlation between gene variants in
tamoxifen metabolizing enymes with primary endpoints in the ATAC trial.
Cancer Res 2010;70:S1-S7Sideras K,
27. Ingle JN, Ames MM, et al. Coprescription of tamoxifen and medications that
inhibit CYP2D6. J Clin Oncol 2010;28:2768-2776. Reid DM,
28. Doughty J, Eastell R, et al. Guidance for the management of breast cancer
treatment-induced bone loss: a consensus position statement from a UK
Expert Group. Cancer Treat Rev 2008;34 Suppl 1:S3-S18.
29. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus
zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679691
30. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase
inhibitor-associated bone loss by zoledronic acid in postmenopausal women
with early breast cancer receiving adjuvant letrozole: ZO-FAST Study
results. Cancer 2008;112:1001-1010.
31. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogenreceptor-poor breast cancer: patient-level meta-analysis of randomised trials.
Lancet 2008;371:29-40.
32. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older
women with early-stage breast cancer. N Engl J Med 2009;360:2055-2065.
33. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy
and hormonal therapy for early breast cancer on recurrence and 15-year
survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
34. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of
randomised studies of adjuvant CMF in operable breast cancer: cohort
study. BMJ 2005;330:217.
35. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival
Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year
Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar
10;27(8):1177-83. Epub 2009 Feb 9.
36. Francis P, Crown J, Di Leo A, et al. Adjuvant chemotherapy with sequential or
concurrent anthracycline and docetaxel: Breast International Group 02-98
randomized trial. J Natl Cancer Inst 2008;100:121-133.
37. Swain SM, Jeong JH, Geyer CE Jr.et al. Longer therapy, iatrogenic
amenorrhea, and survival in early breast cancer. N Engl J Med
2010;362:2053-2065.
38. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and
outcomes of modern chemotherapy for patients with node-positive breast
cancer. JAMA 2006;295:1658-1667.
39. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for
human epidermal growth factor receptor 2 testing in breast cancer. J Clin
Oncol 2007;25:118-145.
40. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B,
Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien
P, Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus
dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus
Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive
or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1;28(1):77-82.
Epub 2009 Nov 9.
41. Adjuvant trastuzumab in HER2-positive breast cancer.AUSlamon D,
Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J,
Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G,
Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A,
Crown J, Breast Cancer International Research GroupSON Engl J Med.
2011;365(14):1273.
42. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2positive breast cancer: a randomised controlled trial.. Smith I, Procter M,
Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M,
Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R,
Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E,
Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team. Lancet.
2007;369(9555):29.
43. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for
operable human epidermal growth factor receptor 2-positive breast cancer:
joint analysis of data from NCCTG N9831 and NSABP B-31. Perez EA,
Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S,
Mamounas EP, Kaufman PA, Wolmark N. J Clin Oncol. 2011;29(25):3366.
44. Tamoxifen added to radiotherapy and surgery for the treatment of ductal
carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F, Barni S, Radiother Oncol. 2011;100(2):195.
45. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates
of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and
B-27. J Clin Oncol 2008;26:778-785.
46. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of
postmenopausal breast cancer patients with letrozole: A randomized doubleblind multicenter study. Ann Oncol 2001;12:1527-1532.
47. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of
postmenopausal breast cancer with anastrozole, tamoxifen, or both in
combination: the Immediate Preoperative Anastrozole, Tamoxifen, or
Combined with Tamoxifen (IMPACT) multicenter double-blind randomized
trial. J Clin Oncol 2005;23:5108-5116.
48. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast
cancer after primary therapy. J Clin Oncol 1996;14:2738-2746.
49. Cardoso F, Bedard PL, Winer EP, et al. On behalf of the ESO-MBC Task Force.
International guidelines for management of metastatic breast cancer:
combination vs sequential single-agent chemotherapy. J Natl Cancer Inst
2009;101:1174-1181.
50. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel
versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol
1999;17:2341-2354.
51. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated patients with
advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:28122823.
52. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel
versus paclitaxel monotherapy in patients with metastatic breast cancer and
prior anthracycline treatment: final results of a global phase III study. J Clin
Oncol 2008;26:3950-3957.
53. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a
monoclonal antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001;344:783-792.
54. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
55. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole
versus anastrozole alone for the treatment of postmenopausal women with
human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III
TAnDEM study. J Clin Oncol 2009;27:5529-5537.
56. Johnston Sn, Pippen J Jr.,Pivot X, et al. Lapatinib combined with letrozole
versus letrozole and placebo as first-line therapy for postmenopausal
hormone receptor-positive metastatic breast cancer. J Clin Oncol
2009;27:5538-5546.
57. Gibson L, Dawson C, Lawrence D, Bliss J. Aromatase inhibitors for treatment
of advanced breast cancer in postmenopausal women. Cochrane Database
Syst Rev 2007;4:CD003370
58. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of
Lapatinib alone or in combination with trastuzumab in women with ErbB2positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol
2010;28:1124-1130.
59. Pagani O, Senkus E, Wood W, et al. International guidelines for management
of metastatic breast cancer: can metastatic breast cancer be cured? J Natl
Cancer Inst 2010;102:456-463
60. Sideras K, Ingle JN, Ames MM, et al. Coprescription of tamoxifen and
medications that inhibit CYP2D6. J Clin Oncol 2010;28:2768-2776.
61. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond
progression in human epidermal growth factor receptor 2-positive advanced
breast cancer: a german breast group 26/breast international group 03-05 study. J
Clin Oncol 2009;27:1999-2006.
62. Trastuzumab treatment in patients with breast cancer and metastatic CNS
disease. Pieńkowski T, Zielinski C. Ann Oncol. 2010;21(5):917.
63. Phase III randomized study comparing docetaxel plus trastuzumab with
vinorelbine plus trastuzumab as first-line therapy of metastatic or locally
advanced human epidermal growth factor receptor 2-positive breast cancer:
the HERNATA study. Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen
K, Jensen AB, Karlsson P, Tange UB, Sørensen PG, Møller S, Bergh J, Langkjer
ST. J Clin Oncol. 2011;29(3):264.
64. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced
Breast Cancer. José Baselga, M.D., Ph.D., Mario Campone, M.D et al.
December 7, 2011 (10.1056/NEJMoa1109653)
65. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive
advanced breast cancer. Di Leo A, Jerusalem G, Petruzelka L, Torres R,
Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser
MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. J Clin
Oncol. 2010;28(30):4594.
66. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment
for advanced breast cancer: results from the FIRST study. Robertson JF,
Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J,
Ellis MJ. J Clin Oncol. 2009;27(27):4530.
67. American Society of Clinical Oncology 2007 update of recommendations for
the use of tumor markers in breast cancer. Harris L, Fritsche H, Mennel R,
Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American
Society of Clinical Oncology. J Clin Oncol. 2007;25(33):5287.
68. American Society of Clinical Oncology Clinical Practice Guideline Update on
the Role of Bone-Modifying Agents in Metastatic Breast Cancer. Published in
the Journal of Clinical Oncology. vol.29, issue 9 (March 20), 2011: pp. 12211227
69. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and
15-year breast cancer death: meta-analysis of individual patient data for 10,801
women in 17 randomised trials.
70. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S,
McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C,
Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.
Lancet. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19
71. Sector resection with and without radiotherapy in early breast cancer.
Presentation of two ongoing prospective multicenter studies in Sweden.
Uppsala/Orebro Breast Cancer Study Group.
Holmberg L.
Acta Oncol. 1989;28(6):927-9.
72. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: An intergroup trial
of regional nodal irradiation in early breast cancer (abstract LBA1003). J Clin
Oncol 2011; 29:779s. Abstract available online at http://www.asco.org.
73. Postoperative radiotherapy in high-risk premenopausal women with breast cancer
who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group
82b Trial.Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F,
Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K
N Engl J Med. 1997;337(14):949.
74. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women
with breast cancer.Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco
VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto
IA N Engl J Med. 1997;337(14):956.
75. Reanalysis and results after 12 years of follow-up in a randomized clinical trial
comparing total mastectomy with lumpectomy with or without irradiation in the
treatment of breast cancer.Fisher B, Anderson S, Redmond CK, Wolmark N,
Wickerham DL, Cronin WM.
N Engl J Med. 1995 Nov 30;333(22):1456-61.
76. Breast-conserving treatment with or without radiotherapy in ductal carcinomain-situ: ten-year results of European Organisation for Research and Treatment
of Cancer randomized phase III trial 10853--a study by the EORTC Breast
Cancer Cooperative Group and EORTC Radiotherapy Group.
EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group,
Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP,
Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ.
J Clin Oncol. 2006 Jul 20;24(21):3381-7. Epub 2006 Jun 26.
77. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
Goodwin A, Parker S, Ghersi D, Wilcken N.
Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000563.